Better safety and quality of life in patients with chronic hepatitis B than in patients with chronic hepatitis C when treated with peginterferon alfa-2a (40KD) (PEGASYS®) monotherapy

被引：0
|
作者：
Marcellin, P
Lau, G
Piratvisuth, T
Luo, KX
Bonino, F
Thongasawat, S
Cooksley, G
Hadziyannis, S
Chutaputti, A
Lu, ZM
Fried, M
Chow, WC
Yurdaydin, C
Berg, T
Pluck, N
机构：
[1] Hop Beaujon, Clichy, France
[2] Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China
[3] Songklanakarin Hosp, Songkhla, Thailand
[4] Nangfang Hosp, Guangzhou, Peoples R China
[5] IRCCS Osped Maggiore, Sci Direct, Milan, Italy
[6] Chiang Mai Univ, Chiang Mai 50000, Thailand
[7] Univ Queensland, Royal Brisbane Hosp, Herston, Qld, Australia
[8] H Dynant Hosp, Athens, Greece
[9] Pramongkutklao Hosp, Bangkok, Thailand
[10] Ruijin Hosp, Shanghai, Peoples R China
[11] Univ N Carolina, Chapel Hill, NC USA
[12] Singapore Gen Hosp, Singapore 0316, Singapore
[13] Ankara Univ, TR-06100 Ankara, Turkey
[14] Charite Humboldt Univ Berlin, Berlin, Germany
[15] Roche, Welwyn Garden City, England
来源：
HEPATOLOGY | 2004年 / 40卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：668A / 668A
页数：1
相关论文
共 50 条
  • [21] Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin
    Snoeck, Eric
    Wade, Janet R.
    Duff, Frank
    Lamb, Matthew
    Jorga, Karin
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (06) : 699 - 709
  • [22] PREDICTIVE FACTORS OF THROMBOCYTOPENIA IN TREATMENT OF CHRONIC HEPATITIS C (CHC) PATIENTS WITH PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN
    Mauss, S.
    Schober, A.
    Lutz, T.
    Moog, G.
    Schuchmann, M.
    Heyne, R.
    John, C.
    Schiffelholz, W.
    Baumgarten, A.
    Hey, K. -H.
    Eisenbach, C.
    Teuber, G.
    Schmidt, W.
    Bruch, H. -R.
    Geyer, P.
    Alshuth, U.
    Hueppe, D.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S185 - S185
  • [23] Predictive Factors of Thrombocytopenia in Treatment of Chronic Hepatitis C (CHC) Patients With Peginterferon Alfa-2a (40KD) and Ribavirin
    Mauss, Stefan
    Schober, Andreas
    Lutz, Thomas
    Moog, Gero
    Schuchmann, Marcus
    Heyne, Renate
    John, Christine
    Schiffelholz, Willibold
    Baumgarten, Axel
    Hey, Karl-Heinz
    Eisenbach, Christoph
    Teuber, Gerlinde
    Schmidt, Wolfgang
    Bruch, Harald-Robert
    Geyer, Peter
    Alshuth, Ulrich
    Hueppe, Dietrich
    GASTROENTEROLOGY, 2011, 140 (05) : S948 - S948
  • [24] Peginterferon alfa-2a (40KD) (PEGASYS®) in combination with ribavirin in African American and Caucasian patients with chronic hepatitis CHCV genotype 1:: Safety and tolerability.
    Howell, C
    Jeffers, LS
    Cassidy, W
    Reddy, R
    Sheridan, S
    Ho, I
    Khouri, S
    Harb, G
    HEPATOLOGY, 2003, 38 (04) : 319A - 319A
  • [25] Response to peginterferon alfa-2a (40KD) (PEGASYS) treatment in patients with bridging fibrosis in HBeAg-positive and HBeAg-negative chronic hepatitis B
    Cooksley, Graham
    Lau, George
    Marcellin, Patrick
    Piratvisuth, Teerha
    Lai, Ming-Yang
    Bonino, Ferruccio
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A32 - A32
  • [26] Cost-effectiveness of peginterferon alfa-2a (40KD) for the treatment of chronic Hepatitis B in Italy
    Eandi, M.
    Iannazzo, S.
    Pradelli, L.
    Patel, K.
    Giuliani, G.
    VALUE IN HEALTH, 2006, 9 (06) : A301 - A302
  • [27] Treatment of chronic hepatitis C (cHC) with peginterferon Alfa-2a (40KD) (PEG) and ribavirin (RBV) in patients older than 60 years
    Meyer, Ulrike
    Zehnter, Elmar
    Mauss, Stefan
    Boeker, Klaus
    Lutz, Thomas
    Racky, Stefan
    Schmidt, Wolfgang
    Ullrich, Rainer
    Sbrijer, Innessa
    Heyne, Renate
    Schober, Andreas
    John, Christine
    Hey, Karl-Heinz
    Bokemeyer, Bernd
    Kallinowski, Birgit
    Moeller, Bernd
    Pape, Stefan
    Alshuth, Ulrich
    Hueppe, Dietrich
    GASTROENTEROLOGY, 2007, 132 (04) : A790 - A791
  • [28] Efficacy and Safety of Peginterferon Alfa-2a (40KD) in Children With Chronic Hepatitis B: The PEG-B-ACTIVE Study
    Wirth, Stefan
    Zhang, Hongfei
    Hardikar, Winita
    Schwarz, Kathleen B.
    Sokal, Etienne
    Yang, Weibo
    Fan, Huimin
    Morozov, Vyacheslav
    Mao, Qing
    Deng, Hong
    Huang, Yang
    Yang, Lei
    Frey, Nicolas
    Nasmyth-Miller, Clare
    Pavlovic, Vedran
    Wat, Cynthia
    HEPATOLOGY, 2018, 68 (05) : 1681 - 1694
  • [29] Peginterferon alfa-2a in patients with chronic hepatitis C
    Zeuzem, S
    Feinman, SV
    Rasenack, J
    Heathcote, EJ
    Lai, MY
    Gane, E
    O'Grady, J
    Reichen, J
    Diago, M
    Lin, A
    Hoffman, J
    Brunda, MJ
    NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (23): : 1666 - 1672
  • [30] The cost effectiveness analysis of treatment with peginterferon alfa-2a (40KD) in patients with hbeag-negative chronic hepatitis B
    Kowalik, E.
    Niewada, M.
    Jakubczyk, M.
    Horban, A.
    Berak, H.
    Szkultecka-Debek, M.
    VALUE IN HEALTH, 2006, 9 (06) : A300 - A300
12345